Voyager Therapeutics Scores $100M Deal with Novartis for Gene Therapies
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has inked a significant deal with Novartis Pharma AG (NYSE: NVS), forming a strategic collaboration and license agreement. The agreement, advised on by legal teams from both companies, includes an up-front payment of $100 million, with $20 million in the form of an equity purchase.
The collaboration aims to advance potential gene therapies for two severe neurological conditions: Huntington's disease (HD) and spinal muscular atrophy (SMA). Voyager's legal counsel, Cooley LLP, played a key role in the assignment of the license. The agreement also makes Voyager eligible for up to an additional $1.2 billion in milestones and tiered royalties on global net sales.
Voyager was advised on the equity investment and general corporate matters by a team including Brian Johnson, Avery Reaves, Sarah Matchett, and Frank Wang. Meanwhile, Sarah Hogan, Elese Hanson, and Drew Fosque guided Voyager through the intricacies of the collaboration and license agreement.
The strategic collaboration between Voyager and Novartis is set to propel the development of innovative gene therapies for HD and SMA. With a substantial up-front payment and potential additional milestones and royalties, this deal signals a significant vote of confidence in Voyager's pipeline.
Read also:
- Chicago Residents Protest ICE Tactics as Federal Agents March Downtown
- Transforming PFAS Identification: The FRED-PFAS Approach
- Phenomenon Known as the Hutchison EffectTraces Its Origins Here
- Uncovered in China: Ancient Pareiasaur Species from the Permian Period Reveals Secrets About Earth's Early Herbivorous Creatures!
